0 of 18 questions completed
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading…
You must sign in or sign up to start the assessment.
You must first complete the following:
0 of 18 questions answered correctly
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Myeloproliferative neoplasms (MPNs) do not include:
The primary driver mutation in MPNs is:
Prognostic models for MPNs include all of the following except:
Symptoms in MPNs includes all of the following except:
Potential treatment for high-risk myelofibrosis patents include(s):
Which is not true for the use of interferon for the treatment of myelofibrosis?
In treating myelofibrosis, ruxolitinib initial dosing is dependent on platelet count and renal/hepatic function.
Toxicities from ruxolitinib include(s):
What is not a consideration in the administration of fedratinib in patients with myelofibrosis?
Treatment for polycythemia vera combines all of the following except:
A typically effective treatment for polycythemia vera associated pruritus is:
Diagnostic criteria for polycythemia vera include(s):
Diagnostic criteria for essential thrombocytopenia include(s):
Anagrelide is does adjusted to:
Side effects of anagrelide can include:
Pruritis from MPNs:
Patients taking hydroxyurea should be
Resources for patients, caregivers, social workers and other HCPs can be found on websites including: